Targets › GRM5
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Psychiatry, Neurology; next expected readout Feb 2027.
G protein-coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. (UniProt, P41594)
Open in Phaseline: the race on GRM5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Noema Pharma | Basimglurant (NOE-101) Metabotropic glutamate receptor 5 modulator | GRM5 | Phase 2 | Trigeminal Neuralgia | Feb 2027 |
| Yale University | Mavoglurant Metabotropic glutamate receptor 5 antagonist | GRM5 | Phase 1 | Alcohol Consumption | May 2028 |
Alcohol Consumption (1) Trigeminal Neuralgia (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.